Novartis recently filed a lawsuit against the Food and Drug Administration in a federal court in Washington, D.C., claiming that the FDA's approval of a generic version of Entresto is unlawful, per a ...

"The Court further finds that FDA did not act arbitrarily by excluding part of Entresto's dosing regimen from MSN's generic drug label," U.S. District Judge Dabney L. Friedrich wrote in her memorandum ...

(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...

The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...

Novartis wasn't successful in convincing a U.S. appeals court to stop MSN Pharmaceuticals' proposed generic of Novartis' Entresto, per a Reuters report. The U.S. Court of Appeals for the Federal ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from approving it ...

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug Entresto ...